Pancreatic serous cystadenocarcinoma

Summary

Pancreatic serous cystadenocarcinoma (MONDO:0003630) is a disease. A subtype of pancreatic serous cystic neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

4 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000		Europe	Validated
Annual incidence	<1 / 1 000 000	0.002	Belgium	Validated
Annual incidence	<1 / 1 000 000	0.002	Finland	Validated
Annual incidence	<1 / 1 000 000	0.001	Germany	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic serous cystadenocarcinoma
Mondo ID	MONDO:0003630
Orphanet	424073
DOID	DOID:5751
ICD-11	1624575808
NCIT	C5724
UMLS	C1335315
MedGen	233832
GARD	0021781
Anatomy (UBERON)	UBERON:0001264
Is cancer (heuristic)	no

Also known as: pancreas serous adenocarcinoma · pancreatic serous cystadenocarcinoma · serous cystadenocarcinoma of pancreas · serous cystadenocarcinoma of the pancreas

Disease family

This is a subtype of pancreatic serous cystic neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › pancreas disorder › pancreatic neoplasm › pancreatic exocrine neoplasm › pancreatic serous cystic neoplasm › pancreatic serous cystadenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.